Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The ...

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Anthropic (ANTHRO) has acquired Coefficient Bio, a biotech focused on developing AI models for biological research, for slightly more than $400M, according to The Information and a report from Eric ...

What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

The move positions Anthropic in a $100B+ drug discovery market that’s ripe for disruption, blending frontier models with ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Discover the Latest in Research Peptides at Biotech Labz Supply Sebastopol, United States - January 3, 2026 / Biotech ...